Table 2.
Parameters Overview of Experimental Groups: Bone Marrow Transplantation Study
| Ldlr−/−← | C57BL/6 |
Siglec-G−/− |
μMT+C57BL/6 |
μMT+Siglec-G−/− |
|---|---|---|---|---|
| (n = 10) | (n = 11) | (n = 13) | (n = 13) | |
|
Metabolic Parametersa | ||||
| Weights (g) | 25.54 ± 0.63 | 25.15 ± 0.67 | 25.72 ± 0.49 | 25.29 ± 0.73 |
| TC (mg/dL) | 758.33 ± 79.47 | 821.59 ± 66.53 | 884.67 ± 92.20 | 925.96 ± 78.29 |
| TG (mg/dL) |
595.83 ± 49.43 |
567.05 ± 48.57 |
661.46 ± 73.94 |
585.58 ± 46.60 |
|
Atherosclerosis | ||||
| en face (% of aorta) | 3.04 ± 0.38 | 0.59 ± 0.15∗∗∗ | 3.11 ± 0.24 | 1.17 ± 0.34∗∗∗ |
| Aortic origin (× 104 μm2/section) | 4.84 ± 1.14 | 4.03 ± 1.13 | ||
| Necrotic area (% of total lesion area) | 5.20 ± 1.48 | 1.09 ± 0.66∗ | ||
| mac-3+ (% of total area) |
54.96 ± 6.57 |
38.60 ± 4.95∗ |
||
|
Hepatic Inflammation | ||||
| Liver cholesterol (μg TC/μg protein) | 0.22 ± 0.04 | 0.19 ± 0.03 | 0.23 ± 0.03 | 0.23 ± 0.03 |
| Liver TG (μg TG/μg protein) | 0.25 ± 0.04 | 0.21 ± 0.02 | 0.25 ± 0.03 | 0.22 ± 0.02 |
| Liver free fatty acids (μg FFA/μg protein) | 0.14 ± 0.01 | 0.12 ± 0.01 | 0.15 ± 0.01 | 0.15 ± 0.01 |
| ALT (U/l) | 109.1 ± 27.2 | 58.8 ± 11.5 | 47.6 ± 4.8 | 38.6 ± 3.0 |
| Mac-1 (# positive cells/mm2) | 120.69 ± 13.08 | 86.72 ± 8.95∗ | 100.68 ± 6.33 | 79.41 ± 5.50∗ |
| Ly6G (# positive cells/mm2) |
79.67 ± 5.82 |
58.58 ± 7.41∗ |
74.40 ± 6.30 |
48.61 ± 4.04∗∗ |
|
Serum Antibody Titers—10 Weeks HFD | ||||
| Total IgM (mg/ml) | 0.47 ± 0.10 | 0.92 ± 0.11∗∗ | 0.55 ± 0.10 | 1.07 ± 0.10∗∗∗ |
| MDA-LDL IgM (RLU/100ms) | 23,939 ± 2,848 | 32,989 ± 1,848∗∗ | 23,514 ± 1,706 | 30,045 ± 943∗∗ |
| CuOx-LDL IgM (RLU/100ms) | 4,877 ± 951 | 12,566 ± 1,583∗∗∗ | 5,714 ± 829 | 11,704 ± 1,045∗∗∗ |
| Total IgG (mg/ml) | 0.47 ± 0.10 | 0.89 ± 0.10∗ | 0.61 ± 0.09 | 0.98 ± 0.27 |
| MDA-LDL IgG (RLU/100ms) | 3,220 ± 633 | 6,126 ± 1,248 | 4,405 ± 701 | 4,012 ± 752 |
| CuOx-LDL IgG (RLU/100ms) |
2,885 ± 754 |
3,476 ± 769 |
1,827 ± 274 |
1,990 ± 452 |
|
Spleen (Absolute Numbers × 106) | ||||
| T cells (CD3+) | 41.93 ± 4.76 | 37.51 ± 3.86 | 67.76 ± 17.05 | 42.90 ± 8.13 |
| B cells (B220+IgM+) | 66.80 ± 9.44 | 74.18 ± 9.22 | 43.85 ± 12.07 | 47.46 ± 13.18 |
| B1 cells (B220+IgM+CD43+) | 3.21 ± 0.38 | 6.15 ± 0.75∗∗ | 2.82 ± 0.60 | 6.04 ± 1.32∗∗ |
| MZ B cells (B220+CD43−CD23−CD21hi) | 1.98 ± 0.35 | 1.56 ± 0.26 | 4.58 ± 1.41 | 2.94 ± 1.28 |
| T2/FO B cells (B220+CD43−CD23+CD21+) | 46.04 ± 5.43 | 54.25 ± 7.49 | 23.47 ± 7.63 | 25.28 ± 8.42 |
| T1 B cells (B220+CD43−CD23−CD21lo) | 3.42 ± 0.77 | 3.46 ± 0.35 | 3.68 ± 2.40 | 2.24 ± 0.72 |
| B220+CD43− CD23− CD21+ |
5.99 ± 1.18 |
5.48 ± 0.67 |
4.16 ± 1.05 |
5.38 ± 2.08 |
|
Peritoneal Cavity (% Viable Cells) | ||||
| B-1a cells (B220+CD11b+CD5+) out of B cells | 17.13 ± 1.40 | 31.85 ± 1.14∗∗∗ | 25.18 ± 0.62 | 46.20 ± 1.07∗∗∗ |
| B-1b cells (B220+CD11b+CD5−) out of B cells | 14.17 ± 1.24 | 12.47 ± 0.97 | 19.45 ± 1.29 | 15.96 ± 0.83∗ |
| B2 cells (B220+CD11b−CD5−) out of B cells | 64.96 ± 2.32 | 48.47 ± 2.00∗∗∗ | 47.40 ± 1.94 | 29.88 ± 1.06∗∗∗ |
| T cells (B220−CD5+) out of total | 11.99 ± 1.19 | 15.07 ± 2.68 | 18.18 ± 5.04 | 13.97 ± 2.89 |
a
Data are shown as mean ± SEM (∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001).